

LILLY COMMENTS ON AXIRON AT JP MORGAN HEALTHCARE CONFERENCE

Acrux (ASX: ACR) today reported that John Lechleiter, Chairman, President and CEO of Eli Lilly & Company included comments on Axiron in a presentation at the JP Morgan Healthcare Conference in San Francisco. During the presentation, Dr Lechleiter commented “We’ve been pleased with the uptake of Axiron since it was launched last spring. The most recent IMS data show we’ve achieved 10% share of market in total prescriptions and that over one in five new patient starts are going to Axiron.”

Contact

Richard Treagus, CEO: 0417 520 509

About Acrux

www.acrux.com.au

- Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.
- Fast-drying, invisible sprays or liquids provide a delivery platform with low or no skin irritation, superior cosmetic acceptability and simple, accurate and flexible dosing. The technology platform is covered by broad and well-differentiated, issued patents.
- Acrux has two products marketed by licensees in the USA, two products approved in Europe, one product in registration in the USA and further products at earlier stages of development.
- Acrux received two 2010 Governor of Victoria Export Awards, including the Victorian Export Award for Innovation Excellence.